Impact of "ASAP" Multidisciplinary Optimization Care Protocol on Clinical Outcome in Elderly Inpatients for Hip Fracture

Sponsor
University of Liege (Other)
Overall Status
Completed
CT.gov ID
NCT04771364
Collaborator
(none)
300
1
37
8.1

Study Details

Study Description

Brief Summary

To compare the impact of ASAP protocol (geriatric advice, early surgery, loco-regional anesthesia and pharmacological adaptation) on elderly patients with hip fracture and clinical outcome.

Condition or Disease Intervention/Treatment Phase
  • Other: ASAP care's protocol

Detailed Description

Retrospective double cohort analysis for ASA physical status 1, 2 and 3 elderly patients >65 years old, scheduled to undergo surgery for hip fracture between January 1st 2019 and January 1st 2021.

The investigator want to confirm the better outcome on 30-days mortality after surgery in patients where the ASAP protocol was applied, starting from 1 January 2020.

ASAP protocol follow the latest international guidelines about hip fracture in elderly patient. The investigator focuses the research about the impact of ASAP protocol on clinical outcome: geriatrician's advice, impact of loco-regional techniques on intra-operative and postoperative pain control, chronic pharmacological therapy's adaptation and 30-days postoperative mortality.

Study Design

Study Type:
Observational
Actual Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Impact of "ASAP" Multidisciplinary Optimization Care Protocol on Clinical Outcome in Elderly Inpatients for Hip Fracture: Retrospective Cohort Study
Actual Study Start Date :
Jan 1, 2019
Actual Primary Completion Date :
Jan 1, 2021
Actual Study Completion Date :
Feb 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Standard care

Patients aged >65 years old scheduled for hip fracture between January 1st 2019 and December 31th 2019. Standard anesthesiology cares were performed, as usual in our hospital institution.

ASAP cohort

Patients aged >65 years old scheduled for hip fracture between January 1st 2020 and December 31th 2020. Standard anesthesiology cares were performed, as usual in our hospital institution, but the investigator focused the attention on these cares' adaptation: early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic therapy.

Other: ASAP care's protocol
Early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic patient's therapy (in particular with regard to sedative, anticholinergic and psychotropic drugs).

Outcome Measures

Primary Outcome Measures

  1. Postoperative complications [7 days]

    Neurological, cardiovascular, pulmonary, renal, infectious and gastrointestinal complications after surgery.

Secondary Outcome Measures

  1. Days of hospitalisation [30 days]

    Total hospitalisation days

  2. 30-days postoperative mortality [30 days]

    Mortality 1 month after surgery

  3. 1-year postoperative mortality [1 year]

    Mortality 1 year after surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Over 65 years old patients with hip fractures between January 1st 2019 and December 31th 2020
Exclusion Criteria:
  • Fracture without indication for surgery

  • Death before surgery

  • Intensive care's or polytrauma patients (> 2 fracture sites) or under pharmacological coma needed before and after surgery.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Liège Liège Belgium 4000

Sponsors and Collaborators

  • University of Liege

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jean François Brichant, Head of Anesthesiology Departement, University of Liege
ClinicalTrials.gov Identifier:
NCT04771364
Other Study ID Numbers:
  • ASAP
First Posted:
Feb 25, 2021
Last Update Posted:
Mar 2, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2022